3rd Biennial Desensitization and DSA Risk Assessment (DATA) 2019
October 31 – November 1, 2019
The methods of ‘desensitization’ in transplant patients to reduce human leukocyte antigen (HLA) molecules against sensitized antibodies are varying, difficult, expensive and not well understood by the transplant community at large. Only a relatively small number of programs are able to desensitize successfully to transplant—each with its own protocols.This course allows leading authorities in desensitization therapies as a means to improve transplantation for highly HLA sensitized patients and focuses on allowing the exchange of ideas and expertise between speakers and audience. These didactics enable attendees information for a more uniform approach to this problem.
• Describe the impact of the new allocation system in the sensitized patient population.
• Explain the impact of antibodies in nonrenal transplants.
• Discuss how pharmacotherapy aids in B-Cell related immunity.
• Recall the latest updates in B-Cell physiology.
• Explain the latest in tissue typing.
Register before October 4 in order to be a part of this educational experience in Orlando today! Registrants may enter the code DATA50 to receive a discount if registered by Friday, October 4 at midnight.